Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00

PANTHER: Prospective randomized phase III trial of tailored and dose-dense versus standard tri-weekly adjuvant chemotherapy for high-risk breast cancer in the modern era of endocrine and anti-HER2 therapy.

10.1200/jco.2016.34.15_suppl.1002 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 1002-1002 ◽

Cited By ~ 1

Author(s):

Jonas C. S. Bergh ◽

Theodoros Foukakis ◽

Gunter von Minckwitz ◽

Nils-Olof Bengtsson ◽

Birgitta Wallberg ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Adjuvant Chemotherapy ◽

Phase Iii ◽

Phase Iii Trial ◽

Dose Dense ◽

Modern Era ◽

High Risk Breast Cancer ◽

High Risk Breast ◽

279 ORAL Basal-like subtype of breast carcinoma predicts poor clinical outcome in patients with high-risk breast cancer treated with high-dose (HD) or dose-dense chemotherapy: Results of multivariate analysis from the WSG-AM-01 phase III trial

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)80577-4 ◽

2005 ◽

Vol 3 (2) ◽

pp. 79

Keyword(s):

Breast Cancer ◽

Multivariate Analysis ◽

Phase Iii ◽

High Dose ◽

Poor Clinical Outcome ◽

Phase Iii Trial ◽

Dose Dense ◽

High Risk Breast Cancer ◽

High Risk Breast ◽

Adjuvant Dose-Dense Sequential Chemotherapy with Epirubicin, CMF and Weekly Paclitaxel in Patients with Resected High-Risk Breast Cancer: A Hellenic Cooperative Oncology Group (HeCOG) Study

Cancer Investigation ◽

10.1080/07357900701829785 ◽

2008 ◽

Vol 26 (5) ◽

pp. 491-498 ◽

Cited By ~ 5

Author(s):

Christos A. Papadimitriou ◽

Pavlos Papakostas ◽

Eleni Timotheadou ◽

Gerasimos Aravantinos ◽

Aristotelis Bamias ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Weekly Paclitaxel ◽

Oncology Group ◽

Sequential Chemotherapy ◽

Dose Dense ◽

High Risk Breast Cancer ◽

High Risk Breast ◽

Dose-dense sequential chemotherapy with epirubicin(E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (≥ 4 +LN). First results of an AGO-trial

10.1200/jco.2004.22.14_suppl.513 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 513-513 ◽

Cited By ~ 37

Author(s):

V. J. Möbus ◽

M. Untch ◽

A. du Bois ◽

H.-J. Lueck ◽

C. Thomssen ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Cancer Patients ◽

Breast Cancer Patients ◽

Sequential Chemotherapy ◽

First Results ◽

Dose Dense ◽

High Risk Breast Cancer ◽

High Risk Breast ◽

Dose-dense sequential chemotherapy with epirubicin(E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (≥ 4 +LN). First results of an AGO-trial

10.1200/jco.2004.22.90140.513 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 513-513 ◽

Cited By ~ 4

Author(s):

V. J. Möbus ◽

M. Untch ◽

A. du Bois ◽

H.-J. Lueck ◽

C. Thomssen ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Cancer Patients ◽

Breast Cancer Patients ◽

Sequential Chemotherapy ◽

First Results ◽

Dose Dense ◽

High Risk Breast Cancer ◽

High Risk Breast ◽

Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial

The Lancet ◽

10.1016/s0140-6736(05)67784-7 ◽

2005 ◽

Vol 366 (9501) ◽

pp. 1935-1944 ◽

Cited By ~ 87

Author(s):

Ulrike Anneliese Nitz ◽

Svjetlana Mohrmann ◽

Johannes Fischer ◽

Walter Lindemann ◽

Wolfgang E Berdel ◽

...

Keyword(s):

High Dose Chemotherapy ◽

Phase Iii ◽

High Dose ◽

Phase Iii Trial ◽

Multicentre Phase ◽

Dose Dense ◽

High Risk Breast Cancer ◽

High Risk Breast ◽

Cell Support ◽

2–48 Comparison of Rapidly Cycled Tandem High-Dose Chemotherapy Plus Peripheral-Blood Stem-Cell Support Versus Dose-dense Conventional Chemotherapy for Adjuvant Treatment of High-Risk Breast Cancer: Results of a Multicentre Phase III Trial

Breast Diseases A Year Book Quarterly ◽

10.1016/s1043-321x(06)80464-9 ◽

2006 ◽

Vol 17 (2) ◽

pp. 186-187

Author(s):

A.D. Elias

Keyword(s):

High Dose Chemotherapy ◽

Phase Iii ◽

High Dose ◽

Phase Iii Trial ◽

Multicentre Phase ◽

Dose Dense ◽

High Risk Breast Cancer ◽

High Risk Breast ◽

Cell Support ◽

Epoetin-alpha reduces red blood cell transfusions (RBC) in high-risk breast cancer patients with adjuvant dose-dense, sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC)

10.1200/jco.2005.23.16_suppl.613 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 613-613 ◽

Cited By ~ 9

Author(s):

U. Michael ◽

C. Jackisch ◽

M. S. Lenhard ◽

A. Du Bois ◽

H.-J. Lueck ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Breast Cancer Patients ◽

Sequential Chemotherapy ◽

Epoetin Alpha ◽

Red Blood Cell Transfusions ◽

Dose Dense ◽

High Risk Breast Cancer ◽

High Risk Breast ◽

Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial

Breast Cancer Research and Treatment ◽

10.1007/s10549-011-1913-4 ◽

2011 ◽

Vol 132 (2) ◽

pp. 609-619 ◽

Cited By ~ 35

Author(s):

Helen Gogas ◽

Urania Dafni ◽

Maria Karina ◽

Christos Papadimitriou ◽

Anna Batistatou ◽

...

Keyword(s):

Breast Cancer ◽

Concomitant Administration ◽

Phase Iii ◽

Oncology Group ◽

Phase Iii Trial ◽

Node Positive ◽

Dose Dense ◽

Postoperative Dose ◽

Positive Breast Cancer

Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group

Annals of Oncology ◽

10.1093/annonc/mdi366 ◽

2005 ◽

Vol 16 (11) ◽

pp. 1762-1771 ◽

Cited By ~ 80

Author(s):

G. Fountzilas ◽

D. Skarlos ◽

U. Dafni ◽

H. Gogas ◽

E. Briasoulis ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Operable Breast Cancer ◽

Phase Iii ◽

Oncology Group ◽

Sequential Chemotherapy ◽

Phase Iii Study ◽

Dose Dense ◽

Postoperative Dose